Alendronate Sodium

Alendronate Sodium
(ah len’ dro nate)
Binosto, Co-Alendronate (CAN), Fosamax, Novo-Alendronate (CAN), PMS-Alendronate (CAN), ratio-Alendronate (CAN)
PREGNANCY CATEGORY C
Drug Classes
Bisphosphonate
Calcium regulator
Therapeutic Actions
Slows normal and abnormal bone resorption without inhibiting bone formation and mineralization.
Indications
  • Treatment and prevention of osteoporosis in postmenopausal women
  • Treatment of men with osteoporosis
  • Treatment of glucocorticoid-induced osteoporosis (Fosamax)
  • Treatment of Paget’s disease of bone in patients with alkaline phosphatase at least two times upper limit of normal, those who are symptomatic, those at risk for future complications (Fosamax)
  • Unlabeled uses: Osteoporosis with spinal cord injury, vitamin D intoxication, hypercalcemia of malignancy; postoperative knee arthroplasty, osteogenesis imperfecta
Available Forms
Tablets—5, 10, 35, 40, 70 mg; effervescent tablet—70 mg
Dosages
Adults
Jul 20, 2016 | Posted by in NURSING | Comments Off on Alendronate Sodium

Full access? Get Clinical Tree

Get Clinical Tree app for offline access